ANOMALI
29.7.2021 17:04:07 CEST | Business Wire | Press release
Anomali , the leader in intelligence-driven cybersecurity solutions, today announced availability of its latest survey conducted by The Harris Poll. The study, which gathered responses from more than 1,000 adults aged 18 and over in the United Kingdom, reveals that more than three-quarters of British adults have cybersecurity fears around the use of COVID-19 digital vaccination cards. Additional findings showed which entities respondents believe are responsible for protecting them against cyberattacks and who they believe the most likely culprits will be.
A majority of respondents predict that a disruptive cyberattack will follow digital vaccine card adoption, findings also reveal confidence levels when it comes to how prepared the nation is to mount a defense. Among key findings:
- 76% have cybersecurity concerns related to COVID-19 digital vaccination cards. Identity theft topped the list at 51%, with fake vaccine cards that could be used to hack smartphones (44%) and data breaches (45%) close behind.
- 89% have smartphones capable of supporting COVID-19 digital vaccination cards. In contrast, a survey conducted a little over a year ago by Anomali and Censuswide showed that half of respondents knew someone that did not possess smartphones necessary to use healthcare technologies such as contract tracing apps.
- 54% say they are “very likely” to use COVID-19 digital vaccination cards if they become a requirement for certain activities, such as traveling, attending sports venues, school attendance, entering a store or government building, etc. However, doubt remains, as 26% said they are “somewhat” likely. A full 21% rejected the idea of using digital vaccine cards, stating they are not likely to use them at all.
- 64% expect that COVID-19 digital vaccination cards will lead to a cyberattack causing “moderate to major” disruption to business, government, and consumers. 27% said that disruption would only be “slight” while 9% do not expect any related disruptions.
- When asked to identify what type of adversary is most likely to carry out a cyberattack related to COVID-19 digital vaccination cards, organized cybercriminal gangs were most frequently cited (42%).
- 64% “somewhat to strongly” agree that government and private business is prepared to defend consumers against a related cyberattack. 74% said the government was most responsible for providing defense.
- Although COVID-19 passport standards haven’t been established, when asked to pick from a list of organizations that will most likely be responsible for creating and managing standards, the government was most frequently cited (55%), the World Health Organization (WHO) came in second (44%).
“Over the course of the pandemic, our intelligence analysts detected thousands of cyberattacks that were taking advantage of people’s desire to consume information online about how COVID-19 was impacting their lives and world. We’ve detected adversaries doing everything from using fake contact tracing apps to hijack smart phones and steal credentials to launching mass phishing campaigns to infect networks with things like ransomware,” said Hugh Njemanze, President, Anomali. “The easing of restrictions, rise in cyberattacks, and consumers’ willingness to use their smartphones to break free from restrictive lockdowns are at a nexus. Organizations responsible for keeping consumers and businesses safe online need to know who the adversaries are, where the attacks are coming from, and how to detect them before they develop into catastrophes.”
- Download the ebook: COVID-19: The Global Health Pandemic and Cybersecurity Challenges
- Read the blog: The COVID-19 Pandemic Changed Everything, Can You Detect the New Normal?
- View the infographic: COVID-19 DIGITAL VACCINE EFFORTS MAY STALL AMID FEARS
Methodology
This survey was conducted online by The Harris Poll on behalf of Anomali from June 30 – July 7, 2021 among 1,007 U.K. adults all ages 18 and older. Raw data were weighted by the following demographic variables where necessary to reflect the general adult population as follows: age, gender, education, region, race, HH size, and marital status. Propensity score weighting was also used to adjust for respondents’ propensity to be online. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated.
Twitter: https://twitter.com/Anomali
LinkedIn: https://www.linkedin.com/company/anomali/
Blog: https://www.anomali.com/blog
About The Harris Poll
The Harris Poll is one of the longest-running surveys in the U.S., tracking public opinion, motivations and social sentiment since 1963. It is now part of Harris Insights & Analytics, a global consulting and market research firm that strives to reveal the authentic values of modern society to inspire leaders to create a better tomorrow. We work with clients in three primary areas; building twenty-first century corporate reputation, crafting brand strategy and performance tracking, and earning organic media through public relations research. Our mission is to provide insights and advisory to help leaders make the best decisions possible.
About Anomali
Anomali is the leader in global intelligence-driven cybersecurity. Our customers rely on us to see and detect threats, stop breaches, stop attackers, elevate resiliency, and improve the productivity of their security operations. Our solutions serve customers around the world in every major industry vertical, including many of the Global 1000. We are a SaaS company that offers native cloud, multi-cloud, on-premises, and hybrid technologies. As an early threat intelligence innovator, Anomali was founded in 2013 and is backed by leading venture firms including Google Ventures, IVP, General Catalyst, and several others. Learn more at www.anomali.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005800/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
